Gut check: new study probes how hepatitis drug changes your microbiome

NCT ID NCT07429864

First seen Feb 25, 2026 · Last updated May 14, 2026 · Updated 11 times

Summary

This study tracks 20 adults with chronic hepatitis delta (a serious liver infection) who are starting a new drug called bulevirtide. Researchers want to see how the drug changes the gut's bacteria and bile acids over 48 weeks, and how those changes relate to inflammation and liver health. The goal is to better understand why some patients respond to treatment and others don't.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MICROBIAL COLONIZATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fondazione Policlinico Universitaro A. Gemelli IRCSS UOC CEMAD

    RECRUITING

    Roma, 00168, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.